Whilst this may partially relate to a reduced TMB71 due to enrichment in non-smoker patients, a non-inflamed tumour microenvironment with reduced tumour infiltrating lymphocytes72 and reduced interferon gamma (IFNγ) signature may also contribute to this insensitivity73, and also to the activation of CD73 adenosine pathway, as a potential therapeutic target for EGFR-mutant NSCLC.74 The gene discussed is IFNG; the disease is neoplasm.